Development of 68Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET

Mol Pharm. 2022 Aug 1;19(8):2971-2979. doi: 10.1021/acs.molpharmaceut.2c00359. Epub 2022 Jul 20.

Abstract

Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [68Ga]Ga-DOTA-HEVNPs was studied in mice. The results indicated that [68Ga]Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.

Keywords: DOTA; gallium-68; hepatitis E viral nanoparticles; hepatotropism; positron emission tomography tracers; virus-like particle.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Gallium Radioisotopes
  • Hepatitis E virus*
  • Mice
  • Nanoparticles*
  • Positron-Emission Tomography / methods
  • Tissue Distribution

Substances

  • Gallium Radioisotopes